

**NEWS RELEASE  
FOR IMMEDIATE RELEASE**

**Contact:**

**Fiona Macnab**

**Executive Publisher**

**Elsevier**

**+44 20 7424 4259**

[hmsmedia@elsevier.com](mailto:hmsmedia@elsevier.com)

**Guidelines for Treatment of Ebola Patients Are Urgently Needed**

**Call to Action from Noted Infectious Diseases Experts Published in the  
*International Journal of Infectious Diseases***

London, United Kingdom, December 9, 2014 – As the Ebola Virus Diseases (EVD) epidemic continues to rage in West Africa, infectious diseases experts call attention to the striking lack of treatment guidelines. With over 16,000 total cases and more than 500 new infections reported per week, and probable underreporting of both cases and fatalities, the medical community still does not have specific approved treatment in place for Ebola, according to an editorial published in the *International Journal of Infectious Diseases*.

Not only are treatment guidelines lacking, but there are conflicting reports of mortality rates and few descriptions of actual treatments being used. What is clear is that the treatments in industrialized nations with well-developed public health systems differ significantly from those in less-developed nations, especially those with histories of civil wars and little health infrastructure. The few data available indicate that simple fluid replacement and correction of electrolyte imbalances will significantly reduce mortality.

According to authors Eskild Petersen, MD, Editor-in-Chief of the *International Journal of Infectious Diseases* and Professor of Tropical Medicine, Department of Infectious Diseases and Clinical Microbiology, Aarhus University Hospital, Aarhus Denmark, and Boubacar Maiga, MD, PhD, Faculty of Medicine, University of Sciences, Techniques and Technology of Bamako, (USTTB), Bamako, Mali, “Very little data has emerged. One published study reported a mortality of 72% but astonishingly the study contained no information on any treatment. Thus the question remains whether the patients included in that study received any treatment at all.”

These experts explain that management of the epidemic has fallen primarily to Non-Governmental Organizations (NGOs), which have not published any treatment result data and have been simply reporting confirmed cases and outcomes. Without data about the success or failure of specific treatments, treatment may only be palliation and “Ebola hospitals” may be no more than hospices intended to isolate cases from the community.

Staffing of treatment facilities is a crucial issue and it can be speculated that the NGOs do not have access to physicians and nurses with knowledge and experience in high-volume fluid replacement and correction of electrolyte imbalance.

The authors suggest that the World Health Organization take the leadership and develop guidelines for treatment including:

- Diagnosis of EVD
- Principles for intravenous fluid replacement
- Principles for measurement and correction of electrolyte imbalance
- Diagnosis and treatment of concomitant malaria
- Guidelines for administration of antibiotics based on suspicion of septicemia
- HIV testing
- Implementation of a reporting system for all EVD treatment facilities with weekly survival figure updates reported for each NGO to ensure quality control, transparency, and optimization of treatment algorithms

Petersen and Maiga further propose that one strategy could be twinning with hospitals in industrialized countries whereby these hospitals adopt an EVD treatment facility and ensure staffing and training. "This of course would need support from national health authorities," they note. "Such a program would ensure that effective intravenous fluid replacement therapy would be provided, which would probably significantly reduce mortality, ensure confidence in treatment facilities from the local population, and thus increase the use of these facilities with earlier admissions and higher proportion of cases treated, isolated, and recovered."

# # #

#### **NOTES FOR EDITORS**

"Guidelines for treatment of patients with Ebola Virus Diseases are urgently needed," by Eskild Petersen, MD, and Boubacar Maiga, MD, PhD. DOI: <http://dx.doi.org/10.1016/j.ijid.2014.12.002>, *International Journal of Infectious Diseases*, Volume 30 (January 2015), published by Elsevier.

Full text of this study is openly available at <http://www.ijidonline.com/article/S1201-9712%2814%2901719-6/fulltext>. Journalists wishing to interview Dr. Eskild Petersen may contact him directly at +45 7845 2817, +45 2073 3223 (mobile), or [eskildp@dadlnet.dk](mailto:eskildp@dadlnet.dk).

#### **ABOUT THE INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES**

The *International Journal of Infectious Diseases* (IJID) is published by the International Society for Infectious Diseases ([www.isid.org](http://www.isid.org)). IJID is a peer-reviewed, open access journal that publishes original clinical and laboratory-based research, together with reports of clinical trials, reviews, and some case reports dealing with the epidemiology, clinical diagnosis, treatment, and control of infectious diseases with particular emphasis placed on those diseases that are most common in under-resourced countries. [www.ijidonline.com](http://www.ijidonline.com)

#### **ABOUT ELSEVIER**

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and

sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect ([www.sciencedirect.com](http://www.sciencedirect.com)), Scopus ([www.scopus.com](http://www.scopus.com)), Elsevier Research Intelligence ([www.elsevier.com/research-intelligence](http://www.elsevier.com/research-intelligence)) and ClinicalKey ([www.clinicalkey.com](http://www.clinicalkey.com)) — and publishes nearly 2,200 journals, including *The Lancet* ([www.thelancet.com](http://www.thelancet.com)) and *Cell* ([www.cell.com](http://www.cell.com)), and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC ([www.reedelsevier.com](http://www.reedelsevier.com)), a world-leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).